Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
D'Angelica, M; Kornprat, P; Gonen, M; Chung, KY; Jarnagin, WR; DeMatteo, RP; Fong, Y; Kemeny, N; Blumgart, LH; Saltz, LB.
Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
Ann Surg Oncol. 2007; 14(2):759-765
Doi: 10.1245/s10434-006-9074-0
Web of Science
PubMed
FullText
FullText_MUG
- Leading authors Med Uni Graz
- Kornprat Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Bevacizumab (bev) is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF). Perioperative bev is now commonly used in patients undergoing hepatic resection. Little is known, however, about the safety of perioperative bev use in the setting of hepatic resection. Computerized pharmacy records were used to identify all patients who received bev between January 2004 and June 2005. Patients who underwent hepatectomy for colorectal metastases and received bev within 12 weeks of surgery were identified and compared with a group of matched historical controls. Thirty-two patients underwent hepatic resection of colorectal cancer metastases and received bev within the specified perioperative period. Sixteen patients received bev before surgery and 24 received bev after surgery. A subset of eight patients received bev both before and after surgery. The median time between bev administration and surgery was 6.9 weeks before (range, 3-15 weeks) and 7.4 weeks after (range, 5-15 weeks). Perioperative complications occurred in 13 patients (40.6%), two of which were considered major complications. There was no statistically significant difference in perioperative morbidity and severity of complications when compared with a set of matched controls. Clinical experience thus far does not indicate a statistically significantly increased risk of perioperative complications with the incorporation of bev into pre- and/or postoperative treatment paradigms. Given the long half-life of bev and the potential for anti-VEGF therapy to impede wound healing and/or liver regeneration, we continue to favor a window of 6 to 8 weeks between bev administration and surgery.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Angiogenesis Inhibitors - adverse effects Angiogenesis Inhibitors - therapeutic use
- Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - therapeutic use
- Antibodies, Monoclonal, Humanized -
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Bevacizumab -
- Case-Control Studies -
- Colorectal Neoplasms - drug therapy Colorectal Neoplasms - pathology Colorectal Neoplasms - surgery
- Female -
- Hepatectomy - statistics & numerical data
- Humans -
- Liver Neoplasms - drug therapy Liver Neoplasms - secondary Liver Neoplasms - surgery
- Male -
- Middle Aged -
- Morbidity -
- Perioperative Care -
- Postoperative Complications - chemically induced Postoperative Complications - epidemiology
- Find related publications in this database (Keywords)
- colorectal metastases
- hepatectomy
- bevacizumab
- bev
- perioperative morbidity